Welcome to our dedicated page for Elite Pharmaceuticals news (Ticker: ELTP), a resource for investors and traders seeking the latest updates and insights on Elite Pharmaceuticals stock.
Elite Pharmaceuticals, Inc. develops, manufactures, and distributes niche generic pharmaceutical products, with product lines focused on immediate-release and controlled-release solid oral dose products. Company news commonly covers FDA approvals for abbreviated new drug applications, commercial launches under the Elite Laboratories label, and licensed distribution relationships with third-party pharmaceutical marketing organizations.
Recurring updates also include quarterly financial results, conference-call announcements, and operating commentary tied to generic product sales. Recent company developments have included methadone hydrochloride tablets, ropinirole extended-release tablets, lisdexamfetamine products, and naltrexone products within Elite's generic drug portfolio.
Elite Pharmaceuticals (OTCQB: ELTP) reported financial results for Q1 FY2025 ended June 30, 2024. Highlights include:
- Consolidated revenues of $18.8 million, up 109% year-over-year
- Operating profits of $3.9 million, increased 144% year-over-year
- Net income attributable to common shareholders of $0.6 million
The significant growth in operating profits was primarily due to higher sales of Elite label products. The company will host a conference call on August 15, 2024, at 11:30 AM EDT to discuss the results and provide business updates. Stockholders can submit questions in advance to dianne@elitepharma.com by August 14, 2024, 7:00 PM EDT.
Elite Pharmaceuticals, Inc. (OTCQB: ELTP), a specialty pharmaceutical company focusing on niche generic products, has announced its upcoming financial release and conference call schedule. The company will release its first quarter financial results for fiscal year 2025 on August 14, 2024. Following this, Elite's management will host a live conference call on August 15, 2024, at 11:30 AM EDT to discuss the financial and operating results, as well as provide a general business update.
Stockholders are encouraged to submit questions to the company prior to the call. The dial-in numbers for the conference are 1-800-346-7359 (domestic) and 1-973-528-0008 (international), with the conference number 98840. An audio replay will be available on the company's website.
Elite Pharmaceuticals announced its fiscal year-end results for March 31, 2024, showing a significant performance boost. The company reported consolidated revenues of $56.6 million, marking a 65% increase from the previous fiscal year. Operating profits surged by 192% to $10.8 million, largely due to the launch of the Elite label product line. Net income attributable to common shareholders stood at $20.1 million. Elite will host a conference call on July 2, 2024, at 11:30 AM EDT to discuss these results and recent business developments. Stockholders are encouraged to submit financial questions in advance.
Elite Pharmaceuticals (OTCQB: ELTP), a specialty pharmaceutical company focusing on niche generic products, announced they will release their fiscal year 2024 financial results on July 1, 2024. To discuss these results, Elite will host a live conference call on July 2, 2024, at 11:30 AM EDT. Shareholders are encouraged to submit their questions by June 28, 2024, for general queries, and by July 1, 2024, for financial queries. The conference call will provide an overview of financial and operating results along with a business update. The call can be accessed via specific dial-in numbers for domestic and international participants.
Elite Pharmaceuticals announced FDA approval for its generic Methotrexate Sodium 2.5 mg tablets. This approval relates to an Abbreviated New Drug Application (ANDA) and adds to Elite's portfolio of niche generic products. The generic Methotrexate, classified as an antimetabolite, will be marketed under Elite Laboratories. According to IQVIA, the generic market for Methotrexate had annual sales of $64.3 million for the twelve months ending March 2024. Elite Pharmaceuticals focuses on developing, manufacturing, and distributing immediate-release and controlled-release solid oral dose products, operating from a cGMP and DEA registered facility in Northvale, NJ.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.